Qiu Qingya, Deng Hui, Song Ping, Liu Yushu, Zhang Mengxian
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Int J Mol Sci. 2025 Apr 4;26(7):3368. doi: 10.3390/ijms26073368.
Glioblastoma, the most common and aggressive primary malignant brain tumor, is characterized by a high rate of recurrence, disability, and lethality. Therefore, there is a pressing need to develop more effective prognostic biomarkers and treatment approaches for glioblastoma. Lactylation, an emerging form of protein post-translational modification, has been closely associated with lactate, a metabolite of glycolysis. Since the initial identification of lactylation sites in core histones in 2019, accumulating evidence has shown the critical role that lactylation plays in glioblastoma development, assessment of poor clinical prognosis, and immunosuppression, which provides a fresh angle for investigating the connection between metabolic reprogramming and epigenetic plasticity in glioblastoma cells. The objective of this paper is to present an overview of the metabolic and epigenetic roles of lactylation in the expanding field of glioblastoma research and explore the practical value of developing novel treatment plans combining targeted therapy and immunotherapy.
胶质母细胞瘤是最常见且侵袭性最强的原发性恶性脑肿瘤，其特点是复发率高、致残率高和致死率高。因此，迫切需要为胶质母细胞瘤开发更有效的预后生物标志物和治疗方法。乳酰化是一种新出现的蛋白质翻译后修饰形式，它与糖酵解的代谢产物乳酸密切相关。自2019年首次在核心组蛋白中鉴定出乳酰化位点以来，越来越多的证据表明乳酰化在胶质母细胞瘤的发展、不良临床预后评估和免疫抑制中发挥着关键作用，这为研究胶质母细胞瘤细胞中代谢重编程与表观遗传可塑性之间的联系提供了一个新的视角。本文的目的是概述乳酰化在不断扩展的胶质母细胞瘤研究领域中的代谢和表观遗传作用，并探讨开发结合靶向治疗和免疫治疗的新型治疗方案的实用价值。
